Keith P Klugman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/783692/publications.pdf

Version: 2024-02-01

347 papers

23,019 citations

75 h-index 138 g-index

353 all docs

353 docs citations

times ranked

353

19247 citing authors

#	Article	IF	CITATIONS
1	Serotype-specific Cardiac Involvement in Pneumococcal Pneumonia. Clinical Infectious Diseases, 2022, 74, 507-508.	2.9	2
2	Innovative vaccine approaches—a Keystone Symposia report. Annals of the New York Academy of Sciences, 2022, 1511, 59-86.	1.8	5
3	Widespread sharing of pneumococcal strains in a rural African setting: proximate villages are more likely to share similar strains that are carried at multiple timepoints. Microbial Genomics, 2022, 8, .	1.0	1
4	A Streptococcus pneumoniae lineage usually associated with pneumococcal conjugate vaccine (PCV) serotypes is the most common cause of serotype 35B invasive disease in South Africa, following routine use of PCV. Microbial Genomics, 2022, 8, .	1.0	4
5	Comparative Genomics of Disease and Carriage Serotype 1 Pneumococci. Genome Biology and Evolution, 2022, 14, .	1.1	3
6	Time for a third-generation pneumococcal conjugate vaccine. Lancet Infectious Diseases, The, 2021, 21, 14-16.	4.6	20
7	Phylogeography and resistome of pneumococcal meningitis in West Africa before and after vaccine introduction. Microbial Genomics, 2021, 7, .	1.0	O
8	Population genetic structure, serotype distribution and antibiotic resistance of Streptococcus pneumoniae causing invasive disease in children in Argentina. Microbial Genomics, 2021, 7, .	1.0	8
9	Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe. Journal of Infectious Diseases, 2021, 224, S352-S359.	1.9	18
10	Streptococcus pneumoniae genomic datasets from an Indian population describing pre-vaccine evolutionary epidemiology using a whole genome sequencing approach. Microbial Genomics, 2021, 7, .	1.0	8
11	Impact of Pneumococcal Conjugate Vaccine on Vaccine Serotype–Specific Pneumonia. Clinical Infectious Diseases, 2021, 73, e1434-e1435.	2.9	1
12	Epidemiology of invasive bacterial infections in pneumococcal conjugate vaccine-vaccinated and -unvaccinated children under 5 years of age in Soweto, South Africa: a cohort study from a high-HIV burden setting. Paediatrics and International Child Health, 2020, 40, 50-57.	0.3	3
13	Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial. Lancet HIV, the, 2020, 7, e91-e103.	2.1	16
14	A mosaic tetracycline resistance gene tet(S/M) detected in an MDR pneumococcal CC230 lineage that underwent capsular switching in South Africa. Journal of Antimicrobial Chemotherapy, 2020, 75, 512-520.	1.3	12
15	Within-host microevolution of Streptococcus pneumoniae is rapid and adaptive during natural colonisation. Nature Communications, 2020, 11, 3442.	5.8	39
16	Leveraging the COVID-19 response to end preventable child deaths from pneumonia. Lancet, The, 2020, 396, 1709-1711.	6.3	8
17	COVID-19 pneumonia and the appropriate use of antibiotics. The Lancet Global Health, 2020, 8, e1453-e1454.	2.9	87
18	Bacterial genome-wide association study of hyper-virulent pneumococcal serotype 1 identifies genetic variation associated with neurotropism. Communications Biology, 2020, 3, 559.	2.0	11

#	Article	IF	CITATIONS
19	Efficacy, duration of protection, birth outcomes, and infant growth associated with influenza vaccination in pregnancy: a pooled analysis of three randomised controlled trials. Lancet Respiratory Medicine,the, 2020, 8, 597-608.	5.2	40
20	Carriage Dynamics of Pneumococcal Serotypes in Naturally Colonized Infants in a Rural African Setting During the First Year of Life. Frontiers in Pediatrics, 2020, 8, 587730.	0.9	8
21	Visualizing variation within Global Pneumococcal Sequence Clusters (GPSCs) and country population snapshots to contextualize pneumococcal isolates. Microbial Genomics, 2020, 6, .	1.0	25
22	Nasopharyngeal Pneumococcal Density during Asymptomatic Respiratory Virus Infection and Risk for Subsequent Acute Respiratory Illness. Emerging Infectious Diseases, 2019, 25, 2040-2047.	2.0	32
23	Association of Laboratory Methods, Colonization Density, and Age With Detection of Streptococcus pneumoniae in the Nasopharynx. American Journal of Epidemiology, 2019, 188, 2110-2119.	1.6	14
24	Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study. Lancet Infectious Diseases, The, 2019, 19, 759-769.	4.6	165
25	International genomic definition of pneumococcal lineages, to contextualise disease, antibiotic resistance and vaccine impact. EBioMedicine, 2019, 43, 338-346.	2.7	168
26	Population versus individual protection by pneumococcal conjugate vaccination. Lancet, The, 2019, 393, 2102-2104.	6.3	7
27	Putative novel cps loci in a large global collection of pneumococci. Microbial Genomics, 2019, 5, .	1.0	14
28	Dynamics of Colonization of Streptococcus pneumoniae Strains in Healthy Peruvian Children. Open Forum Infectious Diseases, 2018, 5, ofy039.	0.4	6
29	Invasive Disease Caused Simultaneously by Dual Serotypes of Streptococcus pneumoniae. Journal of Clinical Microbiology, 2018, 56, .	1.8	13
30	Usefulness of the Serial Measurement of Vi Antibodies. Clinical Infectious Diseases, 2018, 67, 25-26.	2.9	2
31	Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12896-12901.	3.3	141
32	The role of bacterial vaccines in the prevention of influenza mortality. The Lancet Global Health, 2018, 6, e1268-e1269.	2.9	7
33	A Mechanism of Unidirectional Transformation, Leading to Antibiotic Resistance, Occurs within Nasopharyngeal Pneumococcal Biofilm Consortia. MBio, 2018, 9, .	1.8	25
34	Antibiotic prophylaxisâ€"Preventing severe infections and saving lives in poor countries with very high mortality risk. PLoS Medicine, 2018, 15, e1002594.	3.9	1
35	Global Distribution of Invasive Serotype 35D Streptococcus pneumoniae Isolates following Introduction of 13-Valent Pneumococcal Conjugate Vaccine. Journal of Clinical Microbiology, 2018, 56, .	1.8	12
36	Seasonality of respiratory viruses causing hospitalizations for acute respiratory infections in children in Nha Trang, Vietnam. International Journal of Infectious Diseases, 2018, 75, 18-25.	1.5	31

#	Article	IF	Citations
37	Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study. The Lancet Global Health, 2017, 5, e359-e369.	2.9	47
38	The global distribution and diversity of protein vaccine candidate antigens in the highly virulent Streptococcus pnuemoniae serotype 1. Vaccine, 2017, 35, 972-980.	1.7	27
39	Global perspectives on maternal immunisation. Lancet Infectious Diseases, The, 2017, 17, 685-686.	4.6	8
40	Imputing the Direct and Indirect Effectiveness of Childhood Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease by Surveying Temporal Changes in Nasopharyngeal Pneumococcal Colonization. American Journal of Epidemiology, 2017, 186, 435-444.	1.6	26
41	A new paradigm in pneumococcal conjugate vaccination: moving from individual to herd protection. International Journal of Infectious Diseases, 2017, 60, 96-97.	1.5	4
42	Efficacy of Maternal Influenza Vaccination Against All-Cause Lower Respiratory Tract Infection Hospitalizations in Young Infants: Results From a Randomized Controlled Trial. Clinical Infectious Diseases, 2017, 65, 1066-1071.	2.9	65
43	The future of paediatric pneumococcal conjugate vaccines. Lancet Respiratory Medicine, the, 2017, 5, 605-606.	5.2	1
44	Vaccination to reduce antimicrobial resistance. The Lancet Global Health, 2017, 5, e1176-e1177.	2.9	56
45	Multiplex Urinary Antigen Detection for 13 Streptococcus pneumoniae Serotypes Improves Diagnosis of Pneumococcal Pneumonia in South African HIV-Infected Adults. Journal of Clinical Microbiology, 2017, 55, 302-312.	1.8	8
46	Development and characterization of a synthetic DNA, NUversa, to be used as a standard in quantitative polymerase chain reactions for molecular pneumococcal serotyping. FEMS Microbiology Letters, 2017, 364, .	0.7	14
47	Strain Level Streptococcus Colonization Patterns during the First Year of Life. Frontiers in Microbiology, 2017, 8, 1661.	1.5	10
48	An association between decreasing incidence of invasive non-typhoidal salmonellosis and increased use of antiretroviral therapy, Gauteng Province, South Africa, 2003–2013. PLoS ONE, 2017, 12, e0173091.	1.1	17
49	Estimated severe pneumococcal disease cases and deaths before and after pneumococcal conjugate vaccine introduction in children younger than 5 years of age in South Africa. PLoS ONE, 2017, 12, e0179905.	1.1	37
50	Nasopharyngeal Pneumococcal Density Is Associated With Viral Activity but Not With Use of Improved Stoves Among Young Andean Children. Open Forum Infectious Diseases, 2017, 4, ofx161.	0.4	13
51	Contribution of Serologic Assays in the Evaluation of Influenza Virus Infection Rates and Vaccine Efficacy in Pregnant Women: Report From Randomized Controlled Trials. Clinical Infectious Diseases, 2017, 64, 1773-1779.	2.9	12
52	Competitive Dominance within Biofilm Consortia Regulates the Relative Distribution of Pneumococcal Nasopharyngeal Density. Applied and Environmental Microbiology, 2017, 83, .	1.4	17
53	Nasopharyngeal Pneumococcal Density and Evolution of Acute Respiratory Illnesses in Young Children, Peru, 2009–2011. Emerging Infectious Diseases, 2016, 22, 1996-1999.	2.0	48
54	Epidemiology of Serotype 1 Invasive Pneumococcal Disease, South Africa, 2003–2013. Emerging Infectious Diseases, 2016, 22, 261-270.	2.0	19

#	Article	IF	Citations
55	Two cases of serotypeable and non-serotypeable variants of Streptococcus pneumoniae detected simultaneously during invasive disease. BMC Microbiology, 2016, 16, 126.	1.3	2
56	HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine (PCV). PLoS ONE, 2016, 11, e0149104.	1.1	40
57	Typhoid Fever in South Africa in an Endemic HIV Setting. PLoS ONE, 2016, 11, e0164939.	1.1	14
58	Bacterial Density, Serotype Distribution and Antibiotic Resistance of Pneumococcal Strains from the Nasopharynx of Peruvian Children Before and After Pneumococcal Conjugate Vaccine 7. Pediatric Infectious Disease Journal, 2016, 35, 432-439.	1.1	27
59	Prevalence of maternal colonisation with group B streptococcus: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2016, 16, 1076-1084.	4.6	167
60	World Pneumonia Day 2016: pulse oximetry and oxygen. The Lancet Global Health, 2016, 4, e893-e894.	2.9	9
61	Understanding pneumococcal serotype 1 biology through population genomic analysis. BMC Infectious Diseases, 2016, 16, 649.	1.3	22
62	Access to effective antimicrobials: a worldwide challenge. Lancet, The, 2016, 387, 168-175.	6.3	933
63	Nasopharyngeal Pneumococcal Serotypes Before and After Mass Azithromycin Distributions for Trachoma. Journal of the Pediatric Infectious Diseases Society, 2016, 5, 222-226.	0.6	8
64	Phylogenetic Analysis of Invasive Serotype 1 Pneumococcus in South Africa, 1989 to 2013. Journal of Clinical Microbiology, 2016, 54, 1326-1334.	1.8	16
65	Molecular Epidemiology of Rhinovirus Detections in Young Children. Open Forum Infectious Diseases, 2016, 3, ofw001.	0.4	21
66	Surveillance of the impact of pneumococcal conjugate vaccines in developing countries. Human Vaccines and Immunotherapeutics, 2016, 12, 417-420.	1.4	33
67	The Relevance of a Novel Quantitative Assay to Detect up to 40 Major Streptococcus pneumoniae Serotypes Directly in Clinical Nasopharyngeal and Blood Specimens. PLoS ONE, 2016, 11, e0151428.	1.1	36
68	Increased Nasopharyngeal Density and Concurrent Carriage of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Are Associated with Pneumonia in Febrile Children. PLoS ONE, 2016, 11, e0167725.	1.1	39
69	Single-Plex Quantitative Assays for the Detection and Quantification of Most Pneumococcal Serotypes. PLoS ONE, 2015, 10, e0121064.	1.1	30
70	Streptococcus pneumoniae Serotypes and Mortality in Adults and Adolescents in South Africa: Analysis of National Surveillance Data, 2003 - 2008. PLoS ONE, 2015, 10, e0140185.	1.1	17
71	Dynamics of Increasing IFN-Î ³ Exposure on Murine MH-S Cell-Line Alveolar Macrophage Phagocytosis of <i>Streptococcus pneumoniae </i> . Journal of Interferon and Cytokine Research, 2015, 35, 474-479.	0.5	10
72	Undernutrition and pneumonia mortality. The Lancet Global Health, 2015, 3, e735-e736.	2.9	28

#	Article	lF	CITATIONS
73	Live Attenuated Influenza Virus Increases Pneumococcal Translocation and Persistence Within the Middle Ear. Journal of Infectious Diseases, 2015, 212, 195-201.	1.9	21
74	Pneumococcal Capsules and Their Types: Past, Present, and Future. Clinical Microbiology Reviews, 2015, 28, 871-899.	5.7	557
75	Increased Risk for and Mortality From Invasive Pneumococcal Disease in HIV-Exposed but Uninfected Infants Aged &It1 Year in South Africa, 2009–2013. Clinical Infectious Diseases, 2015, 60, 1346-1356.	2.9	91
76	Association between Respiratory Syncytial Virus Activity and Pneumococcal Disease in Infants: A Time Series Analysis of US Hospitalization Data. PLoS Medicine, 2015, 12, e1001776.	3.9	143
77	Influenza Vaccination of Pregnant Women and Protection of Their Infants. Obstetrical and Gynecological Survey, 2015, 70, 3-5.	0.2	4
78	Risk Factors for Invasive Pneumococcal Disease Among Children Less Than 5 Years of Age in a High HIV Prevalence Setting, South Africa, 2010 to 2012. Pediatric Infectious Disease Journal, 2015, 34, 27-34.	1.1	16
79	Clinical and Microbiological Features of (i) Salmonella (li) Meningitis in a South African Population, 2003–2013. Clinical Infectious Diseases, 2015, 61, S272-S282.	2.9	32
80	Evidence for Clonal Expansion After Antibiotic Selection Pressure: Pneumococcal Multilocus Sequence Types Before and After Mass Azithromycin Treatments. Journal of Infectious Diseases, 2015, 211, 988-994.	1.9	30
81	Region-specific diversification of the highly virulent serotype 1 Streptococcus pneumoniae. Microbial Genomics, 2015, 1, e000027.	1.0	27
82	The PneuCarriage Project: A Multi-Centre Comparative Study to Identify the Best Serotyping Methods for Examining Pneumococcal Carriage in Vaccine Evaluation Studies. PLoS Medicine, 2015, 12, e1001903.	3.9	96
83	Clinical Epidemiology of Bocavirus, Rhinovirus, Two Polyomaviruses and Four Coronaviruses in HIV-Infected and HIV-Uninfected South African Children. PLoS ONE, 2014, 9, e86448.	1.1	42
84	220D-F2 from Rubus ulmifolius Kills Streptococcus pneumoniae Planktonic Cells and Pneumococcal Biofilms. PLoS ONE, 2014, 9, e97314.	1.1	19
85	Impact of Experimental Human Pneumococcal Carriage on Nasopharyngeal Bacterial Densities in Healthy Adults. PLoS ONE, 2014, 9, e98829.	1.1	16
86	Population Snapshot of Streptococcus pneumoniae Causing Invasive Disease in South Africa Prior to Introduction of Pneumococcal Conjugate Vaccines. PLoS ONE, 2014, 9, e107666.	1.1	18
87	Prevention of neonatal pneumonia and sepsis via maternal immunisation. The Lancet Global Health, 2014, 2, e679-e680.	2.9	1
88	High Nasopharyngeal Pneumococcal Density, Increased by Viral Coinfection, Is Associated With Invasive Pneumococcal Pneumonia. Journal of Infectious Diseases, 2014, 210, 1649-1657.	1.9	163
89	Defining the Estimated Core Genome of Bacterial Populations Using a Bayesian Decision Model. PLoS Computational Biology, 2014, 10, e1003788.	1.5	72
90	Reply to "No Clinical Association of Live Attenuated Influenza Vaccine with Nasal Carriage of Bacteria or Acute Otitis Media― Specific Recommendations for Future Studies. MBio, 2014, 5, e01173-14.	1.8	4

#	Article	IF	Citations
91	The adult nasopharyngeal microbiome as a determinant of pneumococcal acquisition. Microbiome, 2014, 2, 44.	4.9	82
92	Surveillance for Antimicrobial Drug Resistance in Under-Resourced Countries. Emerging Infectious Diseases, 2014, 20, 434-441.	2.0	72
93	The Emergence of Bacterial "Hopeful Monsters― MBio, 2014, 5, e01550-14.	1.8	35
94	Polyomaviruses-associated respiratory infections in HIV-infected and HIV-uninfected children. Journal of Clinical Virology, 2014, 61, 571-578.	1.6	6
95	Global practices of meningococcal vaccine use and impact on invasive disease. Pathogens and Global Health, 2014, 108, 11-20.	1.0	59
96	Evidence for Soft Selective Sweeps in the Evolution of Pneumococcal Multidrug Resistance and Vaccine Escape. Genome Biology and Evolution, 2014, 6, 1589-1602.	1.1	112
97	Editorial Commentary: A Tale of 2 Pneumococcal Vaccines. Clinical Infectious Diseases, 2014, 58, 925-927.	2.9	8
98	Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in HIV-Infected and -Uninfected Children in South Africa: A Matched Case-Control Study. Clinical Infectious Diseases, 2014, 59, 808-818.	2.9	39
99	Genomic Load from Sputum Samples and Nasopharyngeal Swabs for Diagnosis of Pneumococcal Pneumonia in HIV-Infected Adults. Journal of Clinical Microbiology, 2014, 52, 4224-4229.	1.8	33
100	The Role of Influenza and Parainfluenza Infections in Nasopharyngeal Pneumococcal Acquisition Among Young Children. Clinical Infectious Diseases, 2014, 58, 1369-1376.	2.9	67
101	Cohort Profile: The Study of Respiratory Pathogens in Andean Children. International Journal of Epidemiology, 2014, 43, 1021-1030.	0.9	17
102	Effects of Vaccination on Invasive Pneumococcal Disease in South Africa. New England Journal of Medicine, 2014, 371, 1889-1899.	13.9	308
103	Factors Associated with Ceftriaxone Nonsusceptibility of Streptococcus pneumoniae: Analysis of South African National Surveillance Data, 2003 to 2010. Antimicrobial Agents and Chemotherapy, 2014, 58, 3293-3305.	1.4	11
104	Influenza Vaccination of Pregnant Women and Protection of Their Infants. New England Journal of Medicine, 2014, 371, 918-931.	13.9	463
105	The role of influenza in the severity and transmission of respiratory bacterial disease. Lancet Respiratory Medicine, the, 2014, 2, 750-763.	5.2	62
106	Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respiratory Medicine, the, 2014, 2, 387-394.	5.2	183
107	Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children. Vaccine, 2014, 32, 2359-2363.	1.7	26
108	Herd protection induced by pneumococcal conjugate vaccine. The Lancet Global Health, 2014, 2, e365-e366.	2.9	29

#	Article	IF	CITATIONS
109	Pneumococcal colonisation density: a new marker for disease severity in HIV-infected adults with pneumonia. BMJ Open, 2014, 4, e005953-e005953.	0.8	36
110	Childhood pneumonia in developing countries. Lancet Respiratory Medicine, the, 2013, 1, 574-584.	5.2	100
111	Antibiotic non-susceptibility among Streptococcus pneumoniae and Haemophilus influenzae isolates identified in African cohorts: a meta-analysis of three decades of published studies. International Journal of Antimicrobial Agents, 2013, 42, 482-491.	1.1	32
112	Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: Updated recommendations from the World Health Organization Pneumococcal Carriage Working Group. Vaccine, 2013, 32, 165-179.	1.7	374
113	Influence of bacterial interactions on pneumococcal colonization of the nasopharynx. Trends in Microbiology, 2013, 21, 129-135.	3.5	134
114	The relationship between pneumococcal serotypes and antibiotic resistance. Pediatria Polska, 2013, 88, T25-T37.	0.1	1
115	Antihypertensives suppress the emergence of fluoroquinolone-resistant mutants in pneumococci: An in vitro study. International Journal of Medical Microbiology, 2013, 303, 176-181.	1.5	19
116	Innovations in pneumonia diagnosis and treatment: a call to action on World Pneumonia Day, 2013. The Lancet Global Health, 2013, 1, e326-e327.	2.9	15
117	Quorum-Sensing Systems LuxS/Autoinducer 2 and Com Regulate Streptococcus pneumoniae Biofilms in a Bioreactor with Living Cultures of Human Respiratory Cells. Infection and Immunity, 2013, 81, 1341-1353.	1.0	94
118	Temporal Changes in Pneumococcal Colonization in a Rural African Community With High HIV Prevalence Following Routine Infant Pneumococcal Immunization. Pediatric Infectious Disease Journal, 2013, 32, 1270-1278.	1.1	50
119	Novel Role for the Streptococcus pneumoniae Toxin Pneumolysin in the Assembly of Biofilms. MBio, 2013, 4, e00655-13.	1.8	67
120	Dynamics of Pneumococcal Transmission in Vaccine-NaÃ-ve Children and Their HIV-infected or HIV-uninfected Mothers During the First 2 Years of Life. American Journal of Epidemiology, 2013, 178, 1629-1637.	1.6	24
121	Epidemiology of Invasive Pneumococcal Disease Among High-Risk Adults Since the Introduction of Pneumococcal Conjugate Vaccine for Children. Clinical Infectious Diseases, 2013, 56, e59-e67.	2.9	79
122	Pathogen Replication, Host Inflammation, and Disease in the Upper Respiratory Tract. Infection and Immunity, 2013, 81, 625-628.	1.0	15
123	Density Interactions Among Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in the Nasopharynx of Young Peruvian Children. Pediatric Infectious Disease Journal, 2013, 32, 72-77.	1.1	85
124	Acquisition of Streptococcus pneumoniae in Pneumococcal Conjugate Vaccine-na \tilde{A} -ve South African Children and Their Mothers. Pediatric Infectious Disease Journal, 2013, 32, e192-e205.	1.1	35
125	Expression of Streptococcus pneumoniae Virulence-Related Genes in the Nasopharynx of Healthy Children. PLoS ONE, 2013, 8, e67147.	1.1	29
126	Trimethoprim-Sulfamethoxazole Prophylaxis and Antibiotic Nonsusceptibility in Invasive Pneumococcal Disease. Antimicrobial Agents and Chemotherapy, 2012, 56, 1602-1605.	1.4	20

#	Article	IF	Citations
127	Benefits to mother and child of influenza vaccination during pregnancy. Human Vaccines and Immunotherapeutics, 2012, 8, 130-137.	1.4	25
128	Risk Factors for Multidrug-Resistant Invasive Pneumococcal Disease in South Africa, a Setting with High HIV Prevalence, in the Prevaccine Era from 2003 to 2008. Antimicrobial Agents and Chemotherapy, 2012, 56, 5088-5095.	1.4	25
129	Economic burden of acute lower respiratory tract infection in South African children. Paediatrics and International Child Health, 2012, 32, 65-73.	0.3	17
130	Pneumococcal Polysaccharide Vaccine Efficacy and Routine Use of Conjugate Vaccines in Infants: There Is No Need for a Vaccine Program in Older Adults at Present. Clinical Infectious Diseases, 2012, 55, 1577-1579.	2.9	17
131	Population Snapshot of Invasive Serogroup B Meningococci in South Africa from 2005 to 2008. Journal of Clinical Microbiology, 2012, 50, 2577-2584.	1.8	6
132	Systemic Shigellosis in South Africa. Clinical Infectious Diseases, 2012, 54, 1448-1454.	2.9	41
133	Clonal Analysis of Neisseria meningitidis Serogroup B Strains in South Africa, 2002 to 2006: Emergence of New Clone ST-4240/6688. Journal of Clinical Microbiology, 2012, 50, 3678-3686.	1.8	5
134	The Anticipated Severity of a "1918-Like―Influenza Pandemic in Contemporary Populations: The Contribution of Antibacterial Interventions. PLoS ONE, 2012, 7, e29219.	1.1	17
135	Development of the Respiratory Index of Severity in Children (RISC) Score among Young Children with Respiratory Infections in South Africa. PLoS ONE, 2012, 7, e27793.	1.1	126
136	Invasive Pneumococcal Pneumonia and Respiratory Virus Co-infections. Emerging Infectious Diseases, 2012, 18, 294-297.	2.0	36
137	Rapid Pneumococcal Evolution in Response to Clinical Interventions. Science, 2011, 331, 430-434.	6.0	828
138	Use of 2 pneumococcal common protein real-time polymerase chain reaction assays in healthy children colonized with Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease, 2011, 70, 452-454.	0.8	14
139	A framework for global surveillance of antibiotic resistance. Drug Resistance Updates, 2011, 14, 79-87.	6.5	101
140	Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with community-acquired pneumonia despite high fluoroquinolone usage. International Journal of Medical Microbiology, 2011, 301, 53-57.	1.5	31
141	Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet, The, 2011, 378, 1917-1930.	6.3	789
142	Persistent High Burden of Invasive Pneumococcal Disease in South African HIV-Infected Adults in the Era of an Antiretroviral Treatment Program. PLoS ONE, 2011, 6, e27929.	1,1	47
143	The Remaining Challenge of Pneumonia. Pediatric Infectious Disease Journal, 2011, 30, 1-2.	1.1	145
144	Increased Risk of Death in Human Immunodeficiency Virus-infected Children With Pneumococcal Meningitis in South Africa, 2003–2005. Pediatric Infectious Disease Journal, 2011, 30, 1075-1080.	1.1	17

#	Article	IF	CITATIONS
145	Impact of Pneumococcal Conjugate Vaccination of Infants on Pneumonia and Influenza Hospitalization and Mortality in All Age Groups in the United States. MBio, 2011, 2, e00309-10.	1.8	201
146	Communicating trends in resistance using a drug resistance index. BMJ Open, 2011, 1, e000135-e000135.	0.8	48
147	Contribution of vaccines to our understanding of pneumococcal disease. Philosophical Transactions of the Royal Society B: Biological Sciences, 2011, 366, 2790-2798.	1.8	25
148	International Pneumococcal Clones Match or Exceed the Fitness of Other Strains despite the Accumulation of Antibiotic Resistance. Antimicrobial Agents and Chemotherapy, 2011, 55, 4915-4917.	1.4	7
149	Outpatient Antibiotic Prescribing and Nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003. Clinical Infectious Diseases, 2011, 53, 631-639.	2.9	151
150	The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. Aids, 2011, 25, 453-462.	1.0	65
151	The LuxS-Dependent Quorum-Sensing System Regulates Early Biofilm Formation by Streptococcus pneumoniae Strain D39. Infection and Immunity, 2011, 79, 4050-4060.	1.0	133
152	Maternal Influenza Immunization and Reduced Likelihood of Prematurity and Small for Gestational Age Births: A Retrospective Cohort Study. PLoS Medicine, 2011, 8, e1000441.	3.9	225
153	The case for launch of an international DNA-based birth cohort study. Journal of Global Health, 2011, 1, 39-45.	1.2	4
154	Effects of Clarithromycin, at Sub-MIC Concentrations, on the Growth of Macrolide-Resistant Streptococcus pneumoniae. Chest, 2010, 138, 738A.	0.4	0
155	Role of Streptococcus pneumoniae in Hospitalization for Acute Community-acquired Pneumonia Associated With Culture-confirmed Mycobacterium tuberculosis in Children. Pediatric Infectious Disease Journal, 2010, 29, 1099-1104.	1.1	77
156	Chlorhexidine Maternal-Vaginal and Neonate Body Wipes in Sepsis and Vertical Transmission of Pathogenic Bacteria in South Africa: A Randomized, Controlled Trial. Obstetrical and Gynecological Survey, 2010, 65, 215-216.	0.2	0
157	Invasive Neisseria meningitidis with decreased susceptibility to fluoroquinolones in South Africa, 2009. Journal of Antimicrobial Chemotherapy, 2010, 65, 2258-2260.	1.3	15
158	An Unusual Pneumococcal Sequence Type Is the Predominant Cause of Serotype 3 Invasive Disease in South Africa. Journal of Clinical Microbiology, 2010, 48, 184-191.	1.8	17
159	Association of Serotype with Risk of Death Due to Pneumococcal Pneumonia: A Metaâ€Analysis. Clinical Infectious Diseases, 2010, 51, 692-699.	2.9	297
160	Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa. Aids, 2010, 24, 1351-1360.	1.0	64
161	Marking November 12, 2010 – World Pneumonia Day: Where are we, where are vaccines?. Hum Vaccin, 2010, 6, 922-925.	2.4	5
162	Single report of β-lactam resistance in an invasive Haemophilus influenzae isolate from South Africa mediated by mutations in penicillin-binding protein 3, 2003–2008. International Journal of Antimicrobial Agents, 2010, 36, 480-482.	1.1	1

#	Article	IF	Citations
163	Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine, 2010, 28, 7634-7643.	1.7	80
164	Increased risk of invasive bacterial infections in African people with sickle-cell disease: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2010, 10, 329-337.	4.6	93
165	Invasive infections and sickle-cell disease – Authors' reply. Lancet Infectious Diseases, The, 2010, 10, 593-594.	4.6	3
166	Rationale for Revised Penicillin Susceptibility Breakpoints versus < i > Streptococcus pneumoniae: < /i > Coping with Antimicrobial Susceptibility in an Era of Resistance. Clinical Infectious Diseases, 2009, 48, 1596-1600.	2.9	163
167	In Vitro Evaluation of the Antimicrobial Activity of Ceftaroline against Cephalosporin-Resistant Isolates of <i>Streptococcus pneumoniae</i> . Antimicrobial Agents and Chemotherapy, 2009, 53, 552-556.	1.4	65
168	Genotypic Comparison of Invasive <i>Neisseria meningitidis</i> Serogroup Y Isolates from the United States, South Africa, and Israel, Isolated from 1999 through 2002. Journal of Clinical Microbiology, 2009, 47, 2787-2793.	1.8	16
169	Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup B <i>Neisseria meningitidis</i>). Journal of Infectious Diseases, 2009, 200, 379-389.	1.9	180
170	Pneumonia vaccines for all who need them. Hum Vaccin, 2009, 5, 779-780.	2.4	0
171	Bacterial Pathogens and Death during the 1918 Influenza Pandemic. New England Journal of Medicine, 2009, 361, 2582-2583.	13.9	114
172	Editorial: Breathing New Life Into Pneumonia Epidemiology. American Journal of Epidemiology, 2009, 170, 1067-1068.	1.6	5
173	Molecular Characterization of Emerging Non-Levofloxacin-Susceptible Pneumococci Isolated from Children in South Africa. Journal of Clinical Microbiology, 2009, 47, 1319-1324.	1.8	17
174	Pneumococcal pneumonia and influenza: A deadly combination. Vaccine, 2009, 27, C9-C14.	1.7	120
175	A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic. International Journal of Antimicrobial Agents, 2009. 33, 58-64.	1.1	12
176	Recommendations for treatment of childhood non-severe pneumonia. Lancet Infectious Diseases, The, 2009, 9, 185-196.	4.6	70
177	Chlorhexidine maternal-vaginal and neonate body wipes in sepsis and vertical transmission of pathogenic bacteria in South Africa: a randomised, controlled trial. Lancet, The, 2009, 374, 1909-1916.	6.3	76
178	The Significance of Serotype Replacement for Pneumococcal Disease and Antibiotic Resistance. Advances in Experimental Medicine and Biology, 2009, 634, 121-128.	0.8	17
179	Molecular basis and clonal nature of increasing pneumococcal macrolide resistance in South Africa, 2000–2005. International Journal of Antimicrobial Agents, 2008, 32, 62-67.	1.1	17
180	Antimicrobial susceptibility and molecular epidemiology of Streptococcus pneumoniae isolated from Shanghai, China. International Journal of Antimicrobial Agents, 2008, 32, 386-391.	1.1	33

11

#	Article	IF	CITATIONS
181	<i>Neisseria meningitidis</i> Intermediately Resistant to Penicillin and Causing Invasive Disease in South Africa in 2001 to 2005. Journal of Clinical Microbiology, 2008, 46, 3208-3214.	1.8	29
182	Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet, The, 2008, 371, 1108-1113.	6.3	57
183	Telithromycin Resistance in Streptococcus pneumoniae Is Conferred by a Deletion in the Leader Sequence of erm (B) That Increases rRNA Methylation. Antimicrobial Agents and Chemotherapy, 2008, 52, 435-440.	1.4	32
184	Interspecies Recombination Occurs Frequently in Quinolone Resistance-Determining Regions of Clinical Isolates of <i>Streptococcus pyogenes</i> Antimicrobial Agents and Chemotherapy, 2008, 52, 4191-4193.	1.4	19
185	Novel Approaches to the Identification of <i>Streptococcus pneumoniae</i> i>as the Cause of Communityâ€Acquired Pneumonia. Clinical Infectious Diseases, 2008, 47, S202-S206.	2.9	91
186	Emergence of Endemic Serogroup W135 Meningococcal Disease Associated with a High Mortality Rate in South Africa. Clinical Infectious Diseases, 2008, 46, 377-386.	2.9	88
187	Mortality in Penicillin-Resistant Pneumococcal Meningitis. Pediatric Infectious Disease Journal, 2008, 27, 671-672.	1.1	8
188	Pneumococcal Vaccines and Flu Preparedness. Science, 2007, 316, 49c-50c.	6.0	48
189	Streptococcus pneumoniae. Infectious Diseases in Clinical Practice, 2007, 15, 92-99.	0.1	1
190	Fitness Costs of Fluoroquinolone Resistance in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 2007, 51, 412-416.	1.4	133
191	High-Level Telithromycin Resistance in a Clinical Isolate of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 2007, 51, 1092-1095.	1.4	23
192	Increased Antimicrobial Resistance Among Nonvaccine Serotypes of Streptococcus pneumoniae in the Pediatric Population After the Introduction of 7-Valent Pneumococcal Vaccine in the United States. Pediatric Infectious Disease Journal, 2007, 26, 123-128.	1.1	207
193	HIV and pneumococcal disease. Current Opinion in Infectious Diseases, 2007, 20, 11-15.	1.3	82
194	Resurgence of the Multiresistant Pneumococcus in the United States: A Commentary. Pediatric Infectious Disease Journal, 2007, 26, 473-474.	1.1	14
195	Seasonality, Incidence, and Repeat Human Metapneumovirus Lower Respiratory Tract Infections in an Area With a High Prevalence of Human Immunodeficiency Virus Type-1 Infection. Pediatric Infectious Disease Journal, 2007, 26, 693-699.	1.1	51
196	Herd immunity after pneumococcal conjugate vaccination. Lancet, The, 2007, 370, 218-219.	6.3	15
197	Clinical impact of antibiotic resistance in respiratory tract infections. International Journal of Antimicrobial Agents, 2007, 29, S6-S10.	1.1	29
198	Streptococcus pneumoniae bacteraemia: pharmacodynamic correlations with outcome and macrolide resistanceâ€"a controlled study. International Journal of Antimicrobial Agents, 2007, 30, 264-269.	1.1	21

#	Article	IF	CITATIONS
199	Virulence Characteristics of (i) Klebsiella (i) and Clinical Manifestations of (i) K. pneumoniae (i) Bloodstream Infections. Emerging Infectious Diseases, 2007, 13, 986-993.	2.0	263
200	Meningococcal Disease in South Africa, 1999–2002. Emerging Infectious Diseases, 2007, 13, 273-281.	2.0	37
201	Bacteraemic pneumococcal pneumonia: Impact of HIV on clinical presentation and outcome. Journal of Infection, 2007, 55, 125-135.	1.7	63
202	Pneumococcal vaccination in developing countries. Lancet, The, 2006, 367, 1880-1882.	6.3	158
203	Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children. Journal of Clinical Virology, 2006, 36, 215-221.	1.6	60
204	Fluoroquinolone-resistant <i>Streptococcus pneumoniae</i> . Emerging Infectious Diseases, 2006, 12, 1462-1463.	2.0	16
205	Fluoroquinolone treatment of pneumococcal infections. The Southern African Journal of Epidemiology & Infection: Official Journal of the Sexually Transmitted Diseases, Infectious Diseases and Epidemiological Societies of Southern Africa, 2006, 21, 34-35.	0.2	0
206	Usefulness of C-Reactive Protein to Define Pneumococcal Conjugate Vaccine Efficacy in the Prevention of Pneumonia. Pediatric Infectious Disease Journal, 2006, 25, 30-36.	1.1	85
207	One enzyme inactivates two antibiotics. Nature Medicine, 2006, 12, 19-20.	15.2	6
208	Heterogeneous Macrolide Resistance and Gene Conversion in the Pneumococcus. Antimicrobial Agents and Chemotherapy, 2006, 50, 359-361.	1.4	15
209	Prevalence of First-Step Mutants among Levofloxacin-Susceptible Invasive Isolates of Streptococcus pneumoniae in the United States. Antimicrobial Agents and Chemotherapy, 2006, 50, 1561-1563.	1.4	30
210	Is Combination the Only Issue?. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1474-1474.	2.5	1
211	Quantitative and Qualitative Antibody Response to Pneumococcal Conjugate Vaccine Among African Human Immunodeficiency Virus-Infected and Uninfected Children. Pediatric Infectious Disease Journal, 2005, 24, 410-416.	1.1	91
212	Hidden Epidemic of Macrolide-resistant Pneumococci. Emerging Infectious Diseases, 2005, 11, 802-807.	2.0	105
213	Human Metapneumovirus Genetic Variability, South Africa. Emerging Infectious Diseases, 2005, 11, 1074-1078.	2.0	64
214	Emergence and Spread of <i>Streptococcus pneumoniae </i> with <i>erm </i> (B) and <i>mef </i> (A) Resistance. Emerging Infectious Diseases, 2005, 11, 851-867.	2.0	108
215	Use of Procalcitonin and C-Reactive Protein to Evaluate Vaccine Efficacy against Pneumonia. PLoS Medicine, 2005, 2, e38.	3.9	34
216	Increased Prevalence of Pediatric Pneumococcal Serotypes in Elderly Adults. Clinical Infectious Diseases, 2005, 41, 481-487.	2.9	81

#	Article	IF	CITATIONS
217	Amino Acid Mutations Essential to Production of an Altered PBP 2X Conferring High-Level β-Lactam Resistance in a Clinical Isolate of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 2005, 49, 4622-4627.	1.4	37
218	Altered PBP 2A and Its Role in the Development of Penicillin, Cefotaxime, and Ceftriaxone Resistance in a Clinical Isolate of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 2005, 49, 2002-2007.	1.4	26
219	The Impact of a 9-Valent Pneumococcal Conjugate Vaccine on the Public Health Burden of Pneumonia in HIV-Infected and -Uninfected Children. Clinical Infectious Diseases, 2005, 40, 1511-1518.	2.9	189
220	Nasopharyngeal Carriage of Pneumococcal Pediatric Serotypes: A Risk for Acute and Recurrent Otitis Media in Children and for Invasive Disease in Susceptible Adults. Journal of Infectious Diseases, 2005, 191, 1790-1792.	1.9	6
221	Capsule Homology Does Not Increase the Frequency of Transformation of Linked Penicillin Binding Proteins PBP 1a and PBP 2x in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 2005, 49, 1591-1592.	1.4	2
222	Novel Mechanism of Resistance to Oxazolidinones, Macrolides, and Chloramphenicol in Ribosomal Protein L4 of the Pneumococcus. Antimicrobial Agents and Chemotherapy, 2005, 49, 3554-3557.	1.4	138
223	Interspecies Recombination in Type II Topoisomerase Genes Is Not a Major Cause of Fluoroquinolone Resistance in Invasive Streptococcus pneumoniae Isolates in the United States. Antimicrobial Agents and Chemotherapy, 2005, 49, 779-780.	1.4	20
224	Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infectious Diseases, The, 2005, 5, 481-493.	4.6	624
225	Antimicrobial resistance in developing countries. Part II: strategies for containment. Lancet Infectious Diseases, The, 2005, 5, 568-580.	4.6	221
226	Combination Antibiotic Therapy Lowers Mortality among Severely Ill Patients with Pneumococcal Bacteremia. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 440-444.	2.5	421
227	Emergence of Streptococcus pneumoniae with Very-High-Level Resistance to Penicillin. Antimicrobial Agents and Chemotherapy, 2004, 48, 3016-3023.	1.4	99
228	Gender as a Risk Factor for Both Antibiotic Resistance and Infection with Pediatric Serogroups/Serotypes, in HIVâ€Infected and â€Uninfected Adults with Pneumococcal Bacteremia. Journal of Infectious Diseases, 2004, 189, 1996-2000.	1.9	45
229	Vaccination: A Novel Approach to Reduce Antibiotic Resistance. Clinical Infectious Diseases, 2004, 39, 649-651.	2.9	8
230	Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia. Chest, 2004, 125, 1888-1901.	0.4	92
231	Levofloxacin-Resistant Invasive Streptococcus pneumoniae in the United States: Evidence for Clonal Spread and the Impact of Conjugate Pneumococcal Vaccine. Antimicrobial Agents and Chemotherapy, 2004, 48, 3491-3497.	1.4	107
232	A role for Streptococcus pneumoniae in virus-associated pneumonia. Nature Medicine, 2004, 10, 811-813.	15.2	516
233	Antibiotic Therapy for Klebsiella pneumoniae Bacteremia: Implications of Production of Extended-Spectrum Â-Lactamases. Clinical Infectious Diseases, 2004, 39, 31-37.	2.9	512
234	Vaccines as tools against resistance: the example of pneumococcal conjugate vaccine. Seminars in Pediatric Infectious Diseases, 2004, 15, 86-93.	1.7	29

#	Article	IF	CITATIONS
235	Oral antibiotics for the treatment of severe pneumonia in children. Lancet, The, 2004, 364, 1104-1105.	6.3	6
236	Impact of Haemophilus influenzae Type b Conjugate Vaccine in South Africa and Argentina. Pediatric Infectious Disease Journal, 2004, 23, 842-847.	1.1	42
237	Failures of \hat{I}^2 -Lactam Therapy for Invasive Pneumococcal Disease. Pediatric Infectious Disease Journal, 2004, 23, 980-981.	1.1	0
238	An International Prospective Study of Pneumococcal Bacteremia: Correlation with In Vitro Resistance, Antibiotics Administered, and Clinical Outcome. Clinical Infectious Diseases, 2003, 37, 230-237.	2.9	426
239	Implications for antimicrobial prescribing of strategies based on bacterial eradication. International Journal of Infectious Diseases, 2003, 7, S27-S31.	1.5	7
240	Human Metapneumovirus-Associated Lower Respiratory Tract Infections among Hospitalized Human Immunodeficiency Virus Type 1 (HIV-1)-Infected and HIV-1-Uninfected African Infants. Clinical Infectious Diseases, 2003, 37, 1705-1710.	2.9	113
241	Site-Specific Mutagenesis Analysis of PBP 1A from a Penicillin-Cephalosporin-Resistant Pneumococcal Isolate. Antimicrobial Agents and Chemotherapy, 2003, 47, 387-389.	1.4	28
242	Susceptibility of Yersinia pestis to novel and conventional antimicrobial agents. Journal of Antimicrobial Chemotherapy, 2003, 52, 294-296.	1.3	38
243	The Role of Clonality in the Global Spread of Fluoroquinoloneâ€Resistant Bacteria. Clinical Infectious Diseases, 2003, 36, 783-785.	2.9	36
244	A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV Infection. New England Journal of Medicine, 2003, 349, 1341-1348.	13.9	926
245	Susceptibility of Bacillus anthracis to eleven antimicrobial agents including novel fluoroquinolones and a ketolide. Journal of Antimicrobial Chemotherapy, 2003, 52, 297-299.	1.3	28
246	Emergence of fluoroquinolone-resistant Streptococcus pneumoniae in a South African child in a tuberculosis treatment facility. Pediatric Infectious Disease Journal, 2003, 22, 1020-1021.	1.1	11
247	Correlation between erythromycin and azithromycin resistance in Streptococcus pneumoniae. South African Medical Journal, 2003, 93, 283.	0.2	0
248	Antibiotic resistance and serotype distribution of Streptococcus pneumoniae colonizing rural Malawian children. Pediatric Infectious Disease Journal, 2003, 22, 564-7.	1.1	18
249	Antibiotic prescribing practices for common childhood illnesses in South Africa. South African Medical Journal, 2003, 93, 505-8.	0.2	1
250	In vitro activity of faropenem against respiratory pathogens. Journal of Antimicrobial Chemotherapy, 2002, 49, 575-577.	1.3	9
251	Ineffectiveness of Trimethoprimâ€Sulfamethoxazole Prophylaxis and the Importance of Bacterial and Viral Coinfections in African Children withPneumocystis cariniiPneumonia. Clinical Infectious Diseases, 2002, 35, 1120-1126.	2.9	67
252	Historical Changes in Pneumococcal Serogroup Distribution: Implications for the Era of Pneumococcal Conjugate Vaccines. Clinical Infectious Diseases, 2002, 35, 547-555.	2.9	143

#	Article	IF	CITATIONS
253	The Battle against Emerging Antibiotic Resistance: Should Fluoroquinolones Be Used to Treat Children?. Clinical Infectious Diseases, 2002, 35, 721-727.	2.9	69
254	Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones. Journal of Antimicrobial Chemotherapy, 2002, 49, 173-176.	1.3	48
255	Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatric Infectious Disease Journal, 2002, 21, 14-22.	1.1	59
256	Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatric Infectious Disease Journal, 2002, 21, 315-321.	1.1	88
257	Lower respiratory tract infections associated with influenza A and B viruses in an area with a high prevalence of pediatric human immunodeficiency type 1 infection. Pediatric Infectious Disease Journal, 2002, 21, 291-297.	1.1	69
258	Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa. Pediatric Infectious Disease Journal, 2002, 21, 1004-1007.	1.1	58
259	Defining the potential impact of conjugate bacterial polysaccharide-protein vaccines in reducing the burden of pneumonia in human immunodeficiency virus type 1-infected and -uninfected children. Pediatric Infectious Disease Journal, 2002, 21, 393-399.	1.1	18
260	Analysis of Penicillin-Binding Protein Genes of Clinical Isolates of Streptococcus pneumoniae with Reduced Susceptibility to Amoxicillin. Antimicrobial Agents and Chemotherapy, 2002, 46, 2349-2357.	1.4	75
261	Community-Acquired Klebsiella pneumoniae Bacteremia: Global Differences in Clinical Patterns. Emerging Infectious Diseases, 2002, 8, 160-166.	2.0	476
262	Impact of human immunodeficiency virus type 1 infection on the epidemiology and outcome of bacterial Meningitis in South African children. International Journal of Infectious Diseases, 2001, 5, 119-125.	1.5	49
263	Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance. Lancet Infectious Diseases, The, 2001, 1, 85-91.	4.6	115
264	Streptococcus pneumoniae respiratory tract infections. Current Opinion in Infectious Diseases, 2001, 14, 173-179.	1.3	51
265	Serotype 19F Multiresistant Pneumococcal Clone Harboring Two Erythromycin Resistance Determinants [erm (B) and mef (A)] in South Africa. Antimicrobial Agents and Chemotherapy, 2001, 45, 1595-1598.	1.4	75
266	Emergence of a Pneumococcal Clone with Cephalosporin Resistance and Penicillin Susceptibility. Antimicrobial Agents and Chemotherapy, 2001, 45, 2648-2650.	1.4	25
267	Alterations in MurM, a Cell Wall Muropeptide Branching Enzyme, Increase High-Level Penicillin and Cephalosporin Resistance in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 2001, 45, 2393-2396.	1.4	78
268	Prevalence of Serotypes and Molecular Epidemiology of Streptococcus pneumoniae Strains Isolated from Children in Beijing, China: Identification of Two Novel Multiply-Resistant Clones. Microbial Drug Resistance, 2001, 7, 55-63.	0.9	29
269	Differing manifestations of respiratory syncytial virus-associated severe lower respiratory tract infections in human immunodeficiency virus type 1-infected and uninfected children. Pediatric Infectious Disease Journal, 2001, 20, 164-170.	1.1	62
270	Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatric Infectious Disease Journal, 2000, 19, 1141-1147.	1.1	142

#	Article	IF	Citations
271	LACK OF UTILITY OF SEROTYPING MULTIPLE COLONIES FOR DETECTION OF SIMULTANEOUS NASOPHARYNGEAL CARRIAGE OF DIFFERENT PNEUMOCOCCAL SEROTYPES. Pediatric Infectious Disease Journal, 2000, 19, 1017-1020.	1.1	103
272	Antimicrobial resistance of nasopharyngeal isolates of Streptococcus pneumoniae and Haemophilus influenzae from children in the Central African Republic. Pediatric Infectious Disease Journal, 2000, 19, 438-444.	1.1	24
273	New Gene Cassettes for Trimethoprim Resistance, dfr13, and Streptomycin-Spectinomycin Resistance, aadA4, Inserted on a Class 1 Integron. Antimicrobial Agents and Chemotherapy, 2000, 44, 355-361.	1.4	41
274	Evernimicin (SCH27899) Inhibits a Novel Ribosome Target Site: Analysis of 23S Ribosomal DNA Mutants. Antimicrobial Agents and Chemotherapy, 2000, 44, 3101-3106.	1.4	43
275	Non-Penicillin-Binding Protein Mediated High-Level Penicillin and Cephalosporin Resistance in a Hungarian Clone of Streptococcus pneumoniae. Microbial Drug Resistance, 2000, 6, 105-110.	0.9	29
276	Analysis of Penicillin-Binding Protein1band2aGenes fromStreptococcus pneumoniae. Microbial Drug Resistance, 2000, 6, 127-131.	0.9	18
277	Increased Disease Burden and Antibiotic Resistance of Bacteria Causing Severe Community-Acquired Lower Respiratory Tract Infections in Human Immunodeficiency Virus Type 1-Infected Children. Clinical Infectious Diseases, 2000, 31, 170-176.	2.9	232
278	Mutations in Ribosomal Protein L16 Conferring Reduced Susceptibility to Evernimicin (SCH27899): Implications for Mechanism of Action. Antimicrobial Agents and Chemotherapy, 2000, 44, 732-738.	1.4	41
279	Acquisition of Chloramphenicol Resistance by the Linearization and Integration of the Entire Staphylococcal Plasmid pC194 into the Chromosome of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 2000, 44, 393-395.	1.4	43
280	Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. Journal of Pediatrics, 2000, 137, 78-84.	0.9	162
281	Rationale for a hospital-based pneumococcal vaccine trial for HIV-seropositive South Africans. International Journal of Infectious Diseases, 2000, 4, 231-232.	1.5	1
282	Novel Expansions of the Gene Encoding Dihydropteroate Synthase in Trimethoprim-Sulfamethoxazole-Resistant <i>Streptococcus pneumoniae</i> . Antimicrobial Agents and Chemotherapy, 2000, 44, 1411-1411.	1.4	1
283	Molecular Basis of Rifampin Resistance in <i>Streptococcus pneumoniae</i> . Antimicrobial Agents and Chemotherapy, 1999, 43, 2361-2365.	1.4	51
284	Novel Expansions of the Gene Encoding Dihydropteroate Synthase in Trimethoprim-Sulfamethoxazole-Resistant <i>Streptococcus pneumoniae</i> and Chemotherapy, 1999, 43, 2225-2230.	1.4	44
285	Bacteremic Pneumococcal Pneumonia in HIV-Seropositive and HIV-Seronegative Adults. Chest, 1999, 116, 107-114.	0.4	67
286	Immunogenicity and Impact on Nasopharyngeal Carriage of a Nonavalent Pneumococcal Conjugate Vaccine. Journal of Infectious Diseases, 1999, 180, 1171-1176.	1.9	487
287	EMERGENCE OF DRUG RESISTANCE. Infectious Disease Clinics of North America, 1999, 13, 637-646.	1.9	33
288	Aeromonas Species Isolated from Medicinal Leeches. Annals of Plastic Surgery, 1999, 42, 275-279.	0.5	48

#	Article	IF	CITATIONS
289	Application of <i>pbp1A</i> PCR in Identification of Penicillin-Resistant <i>Streptococcus pneumoniae</i> Journal of Clinical Microbiology, 1999, 37, 628-632.	1.8	22
290	Use of Dorset Egg Medium for Maintenance and Transport of Neisseria meningitidis and Haemophilus influenzae Type b. Journal of Clinical Microbiology, 1999, 37, 2045-2046.	1.8	13
291	Serotypes and antibacterial susceptibility of pneumococci isolated from children with infections in Ankara in relation to proposed pneumococcal vaccine coverage. Pediatrics International, 1998, 40, 437-440.	0.2	11
292	Nasopharyngeal carriage and antimicrobial resistance in isolates of Streptococcus pneumoniae and Haemophilus influenzae type b in children under 5 years of age in Botswana. International Journal of Infectious Diseases, 1998, 3, 18-25.	1.5	62
293	Regional considerations in the use of broad-spectrum quinolones. Drugs and Therapy Perspectives, 1998, 12, 22-22.	0.3	O
294	The Molecular Mechanisms of Tetracycline Resistance in the Pneumococcus. Microbial Drug Resistance, 1998, 4, 79-84.	0.9	26
295	The Clinical Relevance of Antibiotic Resistance in the Management of Pneumococcal Pneumonia. Infectious Diseases in Clinical Practice, 1998, 7, 180-184.	0.1	8
296	The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. Aids, 1998, 12, 2177-2184.	1.0	114
297	Antibiotic Susceptibility Patterns of <i>Streptococcus pneumoniae</i> in China and Comparison of MICs by Agar Dilution and E-Test Methods. Antimicrobial Agents and Chemotherapy, 1998, 42, 2633-2636.	1.4	30
298	Long term serological response to Vi vaccine and protective immunity. Medical Journal of Indonesia, 1998, 7, 88.	0.2	0
299	Alterations in PBP 1A Essential for High-Level Penicillin Resistance in <i>Streptococcus pneumoniae</i> . Antimicrobial Agents and Chemotherapy, 1998, 42, 1329-1333.	1.4	115
300	New Trimethoprim-Resistant Dihydrofolate Reductase Cassette, <i>dfrXV</i> , Inserted in a Class 1 Integron. Antimicrobial Agents and Chemotherapy, 1998, 42, 2221-2224.	1.4	24
301	Rapid Detection of Penicillin-Resistant <i>Streptococcus pneumoniae</i> in Cerebrospinal Fluid by a Seminested-PCR Strategy. Journal of Clinical Microbiology, 1998, 36, 453-457.	1.8	61
302	Long-Term Survival of $\langle i \rangle$ Streptococcus pneumoniae $\langle i \rangle$ at Room Temperature on Dorset Egg Medium. Journal of Clinical Microbiology, 1998, 36, 1139-1140.	1.8	24
303	International Editors: Emerging Infectious Diseasesâ€"South Africa. Emerging Infectious Diseases, 1998, 4, 517-520.	2.0	10
304	Exposures to <i>Legionella pneumophila</i> hand <i>Chlamydia pneumoniae</i> hin South African Mine Workers. International Journal of Occupational and Environmental Health, 1997, 3, 120-127.	1.2	3
305	Three Predominant Clones Identified Within Penicillin-Resistant South African Isolates of Streptococcus pneumoniae. Microbial Drug Resistance, 1997, 3, 385-389.	0.9	48
306	<i>Streptococcus pneumoniae</i> Blood Culture Isolates from Patients with and without Human Immunodeficiency Virus Infection: Alterations in Penicillin Susceptibilities and in Serogroups or Serotypes. Clinical Infectious Diseases, 1997, 25, 1165-1172.	2.9	103

#	Article	lF	CITATIONS
307	Spread of the Spanish Multi-Resistant Serotype 23F Clone of <i>Streptococcus pneumoniae</i> to Seoul, Korea. Microbial Drug Resistance, 1997, 3, 253-257.	0.9	43
308	Pneumococcal infections. Current Opinion in Infectious Diseases, 1997, 10, 109-115.	1.3	21
309	The Clinical Relevance of Antibiotic Resistance in the Management of Pneumococcal Pneumonia. Clinical Pulmonary Medicine, 1997, 4, 190-193.	0.3	3
310	PENETRATION OF CEFPODOXIME INTO MIDDLE EAR FLUID IN PEDIATRIC PATIENTS WITH ACUTE OTITIS MEDIA. Pediatric Infectious Disease Journal, 1997, 16, 79-81.	1.1	12
311	Epidemiology, Control and Treatment of Multiresistant Pneumococci. Drugs, 1996, 52, 42-46.	4.9	38
312	Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients. Pediatric Infectious Disease Journal, 1996, 15, 749-757.	1.1	30
313	Actinobacillus (Pasteurella) ureae meningitis in a HIV-positive patient. Diagnostic Microbiology and Infectious Disease, 1994, 20, 105-107.	0.8	11
314	Pneumococcal resistance to the third-generation cephalosporins: clinical, laboratory and molecular aspects. International Journal of Antimicrobial Agents, 1994, 4, 63-67.	1.1	28
315	Increasing prevalence of penicillin-resistant pneumococcal infections in children in southern Israel. Pediatric Infectious Disease Journal, 1994, 13, 782-786.	1.1	74
316	Neonatal typhoid fever. Pediatric Infectious Disease Journal, 1994, 13, 774-776.	1.1	32
317	RECURRENT PENCILLIN-RESISTANT PNEUMOCOCCAL MENINGITIS AFTER CHLORAMPHENICOL, THERAPY. Pediatric Infectious Disease Journal, 1991, 10, 705-707.	1.1	23
318	Infection of the human orbit by Aspergillus stromatoides. Mycopathologia, 1987, 97, 97-99.	1.3	4
319	Clinical Relevance of Antibiotic Resistance in Pneumococcal Infections. , 0, , 331-338.		0
320	The History of Pneumococcal Disease. , 0, , 1-17.		5
321	Pneumococcal Serotype Epidemiology. , 0, , 139-160.		10
322	Conjugation Chemistry., 0,, 161-174.		2
323	Licensing of Pneumococcal Conjugate Vaccines for Children and Adults: Regulatory Perspective from the European Medicines Agency and the U.S. Food and Drug Administration., 0,, 183-196.		1
324	Functional Assays for Pneumococcal Antibody. , 0, , 213-226.		1

#	Article	IF	CITATIONS
325	Nasopharyngeal Carriage. , 0, , 277-300.		3
326	History of Pneumococcal Immunization., 0,, 19-29.		4
327	Acute Otitis Media and Its Sequelae. , 0, , 301-315.		2
328	Meta-Analysis of the Efficacy of Conjugate Vaccines against Invasive Pneumococcal Disease. , 0, , 317-326.		12
329	Establishing Immune Correlates of Protection. , 0, , 339-349.		4
330	Direct and Indirect Effectiveness and Safety of Pneumococcal Conjugate Vaccine in Practice. , 0, , 351-368.		5
331	Opportunities and Challenges for Pneumococcal Conjugate Vaccines in Low- and Middle-Income Countries., 0,, 405-418.		4
332	Protein Vaccines., 0,, 419-435.		6
333	Animal Models of Invasive Pneumococcal Disease. , 0, , 47-58.		5
334	Animal Models of Pneumococcal Colonization. , 0, , 59-66.		5
335	The Immunobiology of Polysaccharide and Conjugate Vaccines. , 0, , 67-82.		5
336	Efficacy and Safety of Conjugate Pneumococcal Vaccine in the Prevention of Pneumonia., 0,, 327-337.		0
337	Immunogenicity in High-Risk and Immunocompromised Children and Adults. , 0, , 261-275.		O
338	Pneumococcal Vaccines: Manufacture and Quality Control for Product Release., 0,, 175-182.		0
339	Conjugate Vaccines as Probes To Define the Burden of Pneumococcal and Haemophilus influenzae Type b Pneumonia as Well as the Role of Viruses in the Pathogenesis of Pneumonia., 0,, 215-224.		O
340	Immunogenicity and Safety in Adults., 0,, 245-259.		0
341	Immunogenicity and Reactogenicity of Pneumococcal Conjugate Vaccines in Infants and Children. , 0, , 227-243.		O
342	Impact of Conjugate Pneumococcal Vaccine on Antibiotic Resistance. , 0, , 369-385.		0

#	Article	IF	CITATIONS
343	Genetics, Biosynthesis, and Chemistry of Pneumococcal Capsular Polysaccharides., 0,, 31-46.		4
344	Pneumococcal Pneumonia in Adults: Epidemiology, Clinical Features, Diagnosis, and Therapy. , 0, , $117\text{-}138$.		1
345	Epidemiology, Diagnosis, and Treatment of Serious Pneumococcal Infections in Children. , 0, , 93-116.		2
346	Emergence, Spread, and Extinction of Pathogenic Bacterial Clones., 0,, 185-195.		0
347	Pharmacoeconomics of Pneumococcal Conjugate Vaccines. , 0, , 387-403.		1